- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06387368
Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer
April 23, 2024 updated by: Zheng Wang, Health Science Center of Xi'an Jiaotong University
Prospective, Multicenter, Randomized, Parallel Controlled Clinical Study on the Efficacy and Safety of Huaier Granules Combined With Capecitabine Versus Capecitabine Alone in the Treatment of Unresectable Pancreatic Cancer
This is a prospective, multicenter, randomized, open, parallel controlled clinical study to evaluate the efficacy and safety of Huaier Granules combined with capecitabine in the treatment of unresectable pancreatic cancer.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
This study is a prospective, multicenter, randomized, open label, parallel controlled clinical study.
It is expected to include approximately 488 patients diagnosed with unresectable pancreatic adenocarcinoma by tissue or cellular pathology who visited the selected research center from April 2024 to March 2026.
The treatment regimen will be capecitabine monotherapy orally.
Among them, the Huaier group uses "capecitabine+Huaier granules", and is expected to include 244 cases; The control group received capecitabine and is expected to include 244 cases.
Study Type
Interventional
Enrollment (Estimated)
488
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Zheng Wang, PhD
- Phone Number: +8615902993665
- Email: zheng.wang11@mail.xjtu.edu.cn
Study Contact Backup
- Name: Liang Han, PhD
- Phone Number: +8613379181359
- Email: hanliangxjtu@163.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age ≥ 18 years old, regardless of gender.
- The patient has a clear evaluable lesion (RECIST 1.1) and is diagnosed with pancreatic adenocarcinoma through tissue or cellular pathology. Clinical evaluation suggests that radical surgical resection cannot be performed (due to jaundice and gastrointestinal obstruction caused by tumor compression, stent treatment or normal inclusion of biliary and gastrointestinal anastomosis can be performed).
- Patients voluntarily give up conversion therapy, local radiation therapy, targeted immunity, and other programs.
- The patient voluntarily choose chemotherapy, and the plan is to take capecitabine monotherapy orally.
- ECOG score 0-3 points.
- The patients voluntarily participate in and cooperates with all aspects of the research, including but not limited to cooperating with treatment and follow-up, cooperating with the researcher in data collection, not actively taking other treatments, and signing a written informed consent form.
Exclusion Criteria:
- Known to be allergic to the components of Huaier granules or to avoid or use Huaier granules with caution (Huaier group).
- Patients with difficulty swallowing, complete or incomplete gastrointestinal obstruction (excluding those who have undergone gastrointestinal stenting or diversion surgery due to tumor related gastrointestinal obstruction and have a normal diet, can be included in the study normally), active gastrointestinal bleeding, perforation, and other oral medication difficulties.
- After actively reducing jaundice (including but not limited to bile duct/gallbladder puncture external drainage, nasobiliary duct external drainage, biliary stent internal drainage, biliary intestinal anastomosis internal drainage, etc.), the levels of aspartate aminotransferase, alanine aminotransferase, or total bilirubin are still 2.5 times higher than the upper limit of normal values.
- History of merging with other malignant tumors.
- Patients with concomitant myocardial infarction, cerebral infarction, and other thromboembolic diseases requiring surgical treatment.
- Concomitant severe infection.
- Child-Pugh C-grade liver function, renal function 2-5 grades (glomerular filtration rate<90ml/min).
- Pregnant or lactating women or those planning to conceive.
- The patient has received other traditional Chinese patent medicines and simple preparations with anti-tumor effect, chemotherapy or physical therapy in the past 4 weeks(including but not limited to compound cantharidin capsules, cinobufotalin capsules, Kangai injection, please refer to the drug instructions for details).
- Suffering from serious mental illness or other reasons that the researcher deems unsuitable to participate in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Huaier treatment group
The subjects received a combination of Huaier granules and capecitabine regimen.The subject takes Huaier granules orally, 10g once, three times a day; take capecitabine 1250mg/m^2 orally , twice a day (2500mg/m^2/d), day 1-14, once every 3 weeks.
|
Huaier Granules: Oral administration, 10g once, 3 times a day.
Capecitabine: oral administration, 1250mg/m^2, twice a day (2500mg/m^2/d), day 1-14, once every 3 weeks.
Other Names:
|
Active Comparator: Control group
The subjects received the capecitabine monotherapy regimen.
The subjects take capecitabine orally, 1250mg/m^2, twice a day (2500mg/m^2/d), day for 1-14 days, once every 3 weeks.
|
Oral administration, 1250mg/m^2, twice a day (2500mg/m^2/d), day 1-14, once every 3 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: Start of treatment until 2-year follow-up
|
It is defined as the time from the day of patient randomization to death due to any reason.
|
Start of treatment until 2-year follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The incidence and severity of adverse events (AE) and severe adverse events (SAE)
Time Frame: Start of treatment until 2-year follow-up
|
The definitions and severity grading of AE and SAE refer to the corresponding descriptions in the definition and evaluation section of AE.
The incidence rate is defined as the proportion of patients with AE and SAE to the corresponding total population.
|
Start of treatment until 2-year follow-up
|
The incidence and severity of ADR, severe adverse reactions (SADR), suspicious and unexpected severe adverse reactions (SUSAR)
Time Frame: Start of treatment until 2-year follow-up
|
The definitions and severity grading of ADR, severe ADR, and SUSAR refer to the corresponding descriptions in the definition and evaluation section of AE.
The incidence rate is defined as the proportion of patients with ADR, severe ADR, and SUSAR to the corresponding total population.
|
Start of treatment until 2-year follow-up
|
Objective response rate
Time Frame: Start of treatment until 2-year follow-up
|
It is defined as the proportion of patients whose tumors have shrunk to a certain amount and maintained for a certain period of time, generally understood as the sum of CR and PR(CR ,complete remission ,all target lesions disappear, maintained for 4 weeks; PR ,partial remission ,it is defined as a reduction of at least 30% in the sum of the longest diameters of the target lesion compared to baseline, maintained for 4 weeks).
|
Start of treatment until 2-year follow-up
|
Progression free survival
Time Frame: Start of treatment until 2-year follow-up
|
It is defined as the period between the start of treatment and the observation of disease progression or death due to any reason for patients with pancreatic cancer in this study.
|
Start of treatment until 2-year follow-up
|
Conversion surgery rate
Time Frame: Start of treatment until 2-year follow-up
|
It is defined as the proportion of patients diagnosed as locally advanced pancreatic cancer before surgery (stage III) who can accept radical surgery after clinical evaluation; The proportion of patients with oligometastatic lesions (belonging to stage IV) who have no new lesions and significant regression of the metastatic lesions after treatment, and whose primary lesions can be removed (regardless of whether they can be removed before treatment) are clinically assessed as eligible for radical surgery.
|
Start of treatment until 2-year follow-up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Zheng Wang, PhD, First Affiliated Hospital Xi'an Jiaotong University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
May 1, 2024
Primary Completion (Estimated)
March 1, 2028
Study Completion (Estimated)
August 1, 2028
Study Registration Dates
First Submitted
April 23, 2024
First Submitted That Met QC Criteria
April 23, 2024
First Posted (Actual)
April 29, 2024
Study Record Updates
Last Update Posted (Actual)
April 29, 2024
Last Update Submitted That Met QC Criteria
April 23, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Capecitabine
Other Study ID Numbers
- HE-202303
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Cancer Non-resectable
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditionsUnited States
-
UNC Lineberger Comprehensive Cancer CenterRecruitingPancreatic Neoplasms | Pancreas Adenocarcinoma | Pancreatic Cancer Resectable | Cancer of Pancreas | Pancreatic Cancer Non-resectable | Pancreatic Ductal Adenocarcinoma (PDAC) | Pancreatic Cancer, AdultUnited States
-
City of Hope Medical CenterRecruitingPancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Resectable | Pancreatic Carcinoma | Pancreatic Cancer Non-resectable | Pancreatic Cancer Stage III | Pancreatic Cancer Stage | Pancreatic Cancer Stage II | Pancreatic Cancer, Adult | Pancreatic... and other conditionsKorea, Republic of, United States, Japan
-
Asan Medical CenterRecruitingPancreatic Adenocarcinoma | Pancreatic Cancer Non-resectableKorea, Republic of
-
Rise Biopharmaceuticals, Inc.T-TOP Clinical Research Co., Ltd.RecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Non-resectableTaiwan
-
University of OxfordNational Institute for Health Research, United Kingdom; ImunonWithdrawnPancreatic Cancer Metastatic | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Stage IV | Pancreatic Cancer Non-resectableUnited Kingdom
-
University of LouisvilleJames Graham Brown Cancer CenterCompletedPancreatic Cancer Non-resectableUnited States
-
Immunitor LLCUnknownPancreatic Cancer Non-resectableMongolia
-
Shanghai Proton and Heavy Ion CenterRecruitingPancreatic Cancer Non-resectableChina
-
Amsterdam UMC, location VUmcUMC Utrecht; Erasmus Medical Center; Dutch Cancer Society; Viewray Inc.RecruitingPancreatic Cancer Non-resectableNetherlands
Clinical Trials on Huaier Granule
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityQidong Gaitianli Medicines Co., LtdUnknownColorectal CancerChina
-
Tongji HospitalUnknown
-
Shandong UniversityRecruitingTriple Negative Breast CancerChina
-
Qidong Gaitianli Medicines Co., LtdTerminatedNon-small Cell Lung CancerChina
-
Ruijin HospitalNot yet recruitingFallopian Tube Cancer | Peritoneal Cancer | Primary Ovarian Cancer
-
Fudan UniversityHuazhong University of Science and Technology; LinkDoc Technology (Beijing)...RecruitingEarly-stage Breast CancerChina
-
Fudan UniversityHuazhong University of Science and Technology; LinkDoc Technology (Beijing)...RecruitingTriple-negative Breast Cancer | Carcinoma Breast | Invasive Ductal Carcinoma, BreastChina
-
Qidong Gaitianli Medicines Co., LtdHuazhong University of Science and TechnologyCompleted
-
Fudan UniversityHuazhong University of Science and Technology; LinkDoc Technology (Beijing)...Not yet recruitingBreast Cancer Stage IVChina
-
Qidong Gaitianli Medicines Co., LtdHuazhong University of Science and TechnologyTerminated